New JP Draft 2.28 Circular Dichroism Spectroscopy Published for Public Comments
![Statistical Simulations for Enhanced Understanding of Analytical Performance - Live Webinar](files/eca/userImages/training.img/Z-ECA-Webinar-Statistical-Simulations.jpg)
Recommendation
Monday, 9 September 2024 14.00 - 16.00 h
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published a Japanese Pharmacopoeia (JP) draft of a New General Test 2.28 Circular Dichroism Spectroscopy.
The chapter starts with a short introduction to the topic and an explanation of the relevant equations and definitions. The method is defined as follows:
The circular dichroism spectroscopy is a method used to analyze and determine the structure of optically active substances, discriminate active substances from enantiomers, diastereomers, etc by using the phenomenon (circular dichroism) in which the degrees of absorption of left and right circularly polarized lights differ in the absorption wave length region of active substances.
After the general introduction, the new chapter is divided into the following chapters and subchapters:
- 1. Apparatus
- 2. Methods
2.1. Identification test
2.2. Analysis of secondary structure - 3. Verification of the performance of apparatus
3.1. Accuracy of circular dichroism
3.2. Linearity of modulation
The draft document is available as a PDF file on the PMDA's website. Comments can be submitted until September 30, 2021. For this purpose, a form for comments has to be downloaded and sent by e-mail after it has been filled in.
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations